|
1
|
Matsuno S, Egawa S, Fukuyama S, et al:
Pancreatic Cancer Registry in Japan: 20 years of experience.
Pancreas. 28:219–230. 2004.
|
|
2
|
Schmidt CM, Powell ES, Yiannoutsos CT, et
al: Pancreaticoduodenectomy: a 20-year experience in 516 patients.
Arch Surg. 139:718–727. 2004.
|
|
3
|
Höhne MW, Halatsch ME, Kahl GF and Weinel
RJ: Frequent loss of expression of the potential tumor suppressor
gene DCC in ductal pancreatic adenocarcinoma. Cancer Res.
52:2616–2619. 1992.
|
|
4
|
Govindarajan R, Ratnasinghe L, Simmons DL,
et al: Thiazolidinediones and the risk of lung, prostate, and colon
cancer in patients with diabetes. J Clin Oncol. 25:1476–1481.
2007.
|
|
5
|
Choudhary R, Li H, Winn RA, et al:
Peroxisome proliferator-activated receptor-gamma inhibits
transformed growth of non-small cell lung cancer cells through
selective suppression of Snail. Neoplasia. 12:224–234. 2010.
|
|
6
|
Keshamouni VG, Reddy RC, Arenberg DA, et
al: Peroxisome proliferator-activated receptor-gamma activation
inhibits tumor progression in non-small-cell lung cancer. Oncogene.
23:100–108. 2004.
|
|
7
|
Reddy RC, Srirangam A, Reddy K, et al:
Chemotherapeutic drugs induce PPAR-gamma expression and show
sequence-specific synergy with PPAR-gamma ligands in inhibition of
non-small cell lung cancer. Neoplasia. 10:597–603. 2008.
|
|
8
|
Lyon CM, Klinge DM, Do KC, et al:
Rosiglitazone prevents the progression of preinvasive lung cancer
in a murine model. Carcinogenesis. 30:2095–2099. 2009.
|
|
9
|
Olefsky JM: Treatment of insulin
resistance with peroxisome proliferator-activated receptor gamma
agonists. J Clin Inv. 106:467–472. 2000.
|
|
10
|
Braissant O, Foufelle F, Scotto C, Dauça M
and Wahli W: Differential expression of peroxisome
proliferator-activated receptors (PPARs): tissue distribution of
PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology.
137:354–366. 1996.
|
|
11
|
Kliewer SA, Forman BM, Blumberg B, et al:
Differential expression and activation of a family of murine
peroxisome proliferator-activated receptors. Proc Natl Acad Sci
USA. 91:7355–7359. 1994.
|
|
12
|
Tontonoz P, Singer S, Forman BM, et al:
Terminal differentiation of human liposarcoma cells induced by
ligands for peroxisome proliferator-activated receptor gamma and
the retinoid X receptor. Proc Natl Acad Sci USA. 94:237–241.
1997.
|
|
13
|
Mueller E, Sarraf P, Tontonoz P, et al:
Terminal differentiation of human breast cancer through PPAR gamma.
Mol Cell. 1:465–470. 1998.
|
|
14
|
Elstner E, Müller C, Koshizuka K, et al:
Ligands for peroxisome proliferator-activated receptorgamma and
retinoic acid receptor inhibit growth and induce apoptosis of human
breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci
USA. 95:8806–8811. 1998.
|
|
15
|
Sarraf P, Mueller E, Jones D, et al:
Differentiation and reversal of malignant changes in colon cancer
through PPARgamma. Nat Med. 4:1046–1052. 1998.
|
|
16
|
Brockman JA, Gupta RA and Dubois RN:
Activation of PPARgamma leads to inhibition of
anchorage-independent growth of human colorectal cancer cells.
Gastroenterology. 115:1049–1055. 1998.
|
|
17
|
Kitamura S, Miyazaki Y, Shinomura Y, et
al: Peroxisome proliferator-activated receptor gamma induces growth
arrest and differentiation markers of human colon cancer cells. Jpn
J Cancer Res. 90:75–80. 1999.
|
|
18
|
Kubota T, Koshizuka K, Williamson EA, et
al: Ligand for peroxisome proliferator-activated receptor gamma
(troglitazone) has potent antitumor effect against human prostate
cancer both in vitro and in vivo. Cancer Res. 58:3344–3352.
1998.
|
|
19
|
Takahashi N, Okumura T, Motomura W, et al:
Activation of PPARgamma inhibits cell growth and induces apoptosis
in human gastric cancer cells. FEBS Lett. 455:135–139. 1999.
|
|
20
|
Elnemr A, Ohta T, Iwata K, et al:
PPARgamma ligand (thiazolidinedione) induces growth arrest and
differentiation markers of human pancreatic cancer cells. Int J
Oncol. 17:1157–1164. 2000.
|
|
21
|
Itami A, Watanabe G, Shimada Y, et al:
Ligands for peroxisome proliferator-activated receptor gamma
inhibit growth of pancreatic cancers both in vitro and in vivo. Int
J Cancer. 94:370–376. 2001.
|
|
22
|
Galli A, Ceni E, Crabb DW, et al:
Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic
cancer cells via PPARgamma independent mechanisms. Gut.
53:1688–1697. 2004.
|
|
23
|
Pignatelli M, Cortés-Canteli M, Lai C,
Santos A and Perez-Castillo A: The peroxisome
proliferator-activated receptor gamma is an inhibitor of ErbBs
activity in human breast cancer cells. J Cell Sci. 114:4117–4126.
2001.
|
|
24
|
Yoshizumi T, Ohta T, Ninomiya I, et al:
Thiazolidinedione, a peroxisome proliferator-activated
receptor-gamma ligand, inhibits growth and metastasis of HT-29
human colon cancer cells through differentiation-promoting effects.
Int J Oncol. 25:631–639. 2004.
|
|
25
|
Panigrahy D, Singer S, Shen LQ, et al:
PPARgamma ligands inhibit primary tumor growth and metastasis by
inhibiting angiogenesis. J Clin Invest. 110:923–932. 2002.
|
|
26
|
Takano S, Kubota T, Nishibori H, et al:
Pioglitazone, a ligand for peroxisome proliferator-activated
receptor-gamma acts as an inhibitor of colon cancer liver
metastasis. Anticancer Res. 28:3593–3599. 2008.
|
|
27
|
Ninomiya I, Terada I, Yoshizumi T, et al:
Anti-metastatic effect of capecitabine on human colon cancer
xenografts in nude mouse rectum. Int J Cancer. 112:135–142.
2004.
|
|
28
|
Motomura W, Okumura T, Takahashi N, Obara
T and Kohgo Y: Activation of Peroxisome Proliferator-activated
Receptor gamma by Troglitazone Inhibits Cell Growth through the
Increase of p27Kip1 in Human Pancreatic Carcinoma Cells.
Cancer Res. 60:5558–5564. 2000.
|
|
29
|
Kawa S, Nikaido T, Unno H, et al: Growth
inhibition and differentiation of pancreatic cancer cell lines by
PPAR gamma ligand troglitazone. Pancreas. 24:1–7. 2002.
|
|
30
|
Allum WH, Stokes HJ, Macdonald F and
Fielding JW: Demonstration of carcinoembryonic antigen (CEA)
expression in normal, chronically inflamed, and malignant
pancreatic tissue by immunohistochemistry. J Clin Pathol.
39:610–614. 1986.
|
|
31
|
Blin N and Stafford DW: A general method
for isolation of high molecular weight DNA from eukaryotes. Nucleic
Acids Res. 3:2303–2308. 1976.
|
|
32
|
Xie K: Interleukin-8 and human cancer
biology. Cytokine Growth Factor Rev. 12:375–391. 2001.
|
|
33
|
Kuwada Y, Sasaki T, Morinaka K, et al:
Potential involvement of IL-8 and its receptors in the invasiveness
of pancreatic cancer cells. Int J Oncol. 22:765–771. 2003.
|
|
34
|
Shi Q, Abbruzzese JL, Huang S, et al:
Constitutive and inducible interleukin 8 expression by hypoxia and
acidosis renders human pancreatic cancer cells more tumorigenic and
metastatic. Clin Cancer Res. 5:3711–3721. 1999.
|
|
35
|
Le X, Shi Q, Wang B, et al: Molecular
regulation of constitutive expression of interleukin-8 in human
pancreatic adenocarcinoma. J Interferon Cytokine Res. 20:935–946.
2000.
|
|
36
|
Koch AE, Polverini PJ, Kunkel SL, et al:
Interleukin-8 as a macrophage-derived mediator of angiogenesis.
Science. 258:1798–1801. 1992.
|
|
37
|
Wolfe MM, Lichtenstein DR and Singh G:
Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N
Engl J Med. 340:1888–1899. 1999.
|
|
38
|
Masferrer JL, Seibert K, Zweifel B and
Needleman P: Endogenous glucocorticoids regulate an inducible
cyclooxygenase enzyme. Proc Natl Acad Sci USA. 89:3917–3921.
1992.
|
|
39
|
Kujubu DA, Fletcher BS, Varnum BC, Lim RW
and Herschman HR: TIS10, a phorbol ester tumor promoter-inducible
mRNA from Swiss 3T3 cells, encodes a novel prostaglandin
synthase/cyclooxygenase homologue. J Biol Chem. 266:12866–12872.
1991.
|
|
40
|
Masferrer JL, Leahy KM, Koki AT, et al:
Antiangiogenic and antitumor activities of cyclooxygenase-2
inhibitors. Cancer Res. 60:1306–1311. 2000.
|
|
41
|
Ninomiya I, Nagai N, Oyama K, et al:
Antitumor and anti-metastatic effects of cyclooxygenase-2
inhibition by celecoxib on human colorectal carcinoma xenografts in
nude mouse rectum. Oncol Rep. 28:777–784. 2012.
|
|
42
|
Seshasai SR, Kaptoge S, Thompson A, et al:
Emerging Risk Factors Collaboration: Diabetes mellitus, fasting
glucose, and risk of cause-specific death. N Engl J Med.
364:829–841. 2011.
|
|
43
|
Singh S, Singh PP, Singh AG, et al:
Anti-diabetic medications and risk of pancreatic cancer in patients
with diabetes mellitus: a systematic review and meta-analysis. Am J
Gastroenterol. 108:510–519. 2013.
|
|
44
|
Cohen SM: Effects of PPARgamma and
combined agonists on the urinary tract of rats and other species.
Toxicol Sci. 87:322–327. 2005.
|
|
45
|
Tannehill-Gregg SH, Sanderson TP, Minnema
D, et al: Rodent carcinogenicity profile of the antidiabetic dual
PPAR alpha and gamma agonist muraglitazar. Toxicol Sci. 98:258–270.
2007.
|
|
46
|
Lewis JD, Ferrara A, Peng T, et al: Risk
of bladder cancer among diabetic patients treated with
pioglitazone: interim report of a longitudinal cohort study.
Diabetes Care. 34:916–922. 2011.
|
|
47
|
Ferrara A, Lewis JD, Quesenberry CP Jr, et
al: Cohort study of pioglitazone and cancer incidence in patients
with diabetes. Diabetes Care. 34:923–929. 2011.
|
|
48
|
Zhu Z, Shen Z, Lu Y, Zhong S and Xu C:
Increased risk of bladder cancer with pioglitazone therapy in
patients with diabetes: A meta-analysis. Diabetes Res Clin Pract.
98:159–163. 2012.
|
